Rare disease

Atypical haemolytic uraemic syndrome

7 clinical trials

Quick filters

Clinical trials for Atypical haemolytic uraemic syndrome

7 trials across Europe

See all trials →

Quick filters

7 Clinical trials

Atypical haemolytic uraemic syndrome

Recruiting

Registered drugNo placebo

Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Eculizumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Atypical haemolytic uraemic syndrome

Recruiting

InvestigationalNo placebo

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

Atypical haemolytic uraemic syndrome

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

Atypical haemolytic uraemic syndrome

Not recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Belgium

Participants:0–17 years
Substances:Crovalimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Atypical haemolytic uraemic syndrome

Not recruiting

InvestigationalNo placebo

Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Crovalimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Atypical haemolytic uraemic syndrome

Not recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Iptacopan
Sponsor:Novartis Pharma AG

Contact Research Centre

See all trials →

Atypical haemolytic uraemic syndrome

Clinical trials for Atypical haemolytic uraemic syndrome

Atypical haemolytic uraemic syndrome

Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

Atypical haemolytic uraemic syndrome

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical haemolytic uraemic syndrome

Study on Long-Term Safety and Effects of Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical haemolytic uraemic syndrome

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical haemolytic uraemic syndrome

Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical haemolytic uraemic syndrome

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.